NeuroCores
Private Company
Total funding raised: $5M
Overview
NeuroCores is a private, pre-clinical biotech company pioneering a novel approach to treating severe neurological conditions by targeting plasmalogen deficiency. The company's lead compound, KIT-13, is an oral small molecule for Rett syndrome that has demonstrated safety and efficacy in mouse models and has secured both FDA Orphan Drug and Rare Pediatric Disease designations. Founded in 2016 as a spin-out from Japanese research, NeuroCores is led by a team with deep neuroscience and biotech commercialization experience. The company operates at the intersection of high unmet medical need and a potentially transformative platform technology, positioning it for significant value creation if clinical translation is successful.
Technology Platform
Proprietary platform for developing synthetic, orally bioavailable plasmalogen derivatives designed to cross the blood-brain barrier to address plasmalogen deficiency, a root cause of neuroinflammation, mitochondrial dysfunction, and impaired neuronal function.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
NeuroCores operates in a niche but competitive space. While few companies are directly developing synthetic plasmalogen derivatives, it competes broadly with other biotechs targeting neuroinflammation, mitochondrial dysfunction, and synaptic health in rare pediatric and neurodegenerative diseases. Its specific Japanese research heritage and lead compound's designations provide a distinct, though early, competitive position.